Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion. The main object of the takeover is ...

an immunology drug acquired in Davis’ $10.8 billion buyout of Prometheus Biosciences. That adds up to a potential $35 billion ...

Merck now finds itself in the same precarious ... and acquisitions like the $11 billion purchase of immunology-focused ...

Merck has taken steps in mergers and acquisition to diversify its pipeline and product offerings, including the $10.8 billion acquisition of Prometheus Biosciences and a major licensing deal with ...

Merck issued a US$6bn jumbo bond on Monday to help fund its US$10.8bn acquisition of Prometheus Biosciences that will give the pharmaceutical giant a foothold in therapies for immune diseases as it ...

Merck embraces precision medicine and leverages data from Prometheus and applies its oncology expertise to inflammatory bowel disease. Their pipeline aims to transform treatments for chronic ...